France
AdipoPharma SAS, a cutting-edge French biotech company, is spearheading innovative research targeting adipocyte cells to tackle insulin resistance, type 2 diabetes, and associated comorbidities. Founded in 2022, the company is making strides with its first-in-class candidate, PATAS, which is poised to enter clinical trials later this year.
Anchored in France, with a subsidiary in the U.S., AdipoPharma is committed to exploring the unique effects of lipid biosynthesis and managing whole-body lipid homeostasis as a therapeutic approach. The recent Venture Round investment on 11 November 2024, backed by key investors including Good Growth Capital, Newton BioCapital, Sambrinvest, INVESTSUD, and Okeanos, reflects solid confidence in the company's potential to transform diabetes treatment.
Operating within the Biotechnology and Pharmaceutical industries, AdipoPharma represents a promising investment opportunity in the burgeoning biotech sector.
